Of the three RAS
oncoproteins, only HRAS is delocalized and inactivated by
farnesyltransferase inhibitors (FTI), an approach yet to be exploited clinically. In this study, we treat mice bearing Hras-driven poorly differentiated and
anaplastic thyroid cancers (Tpo-Cre/HrasG12V/p53flox/flox ) with the FTI
tipifarnib. Treatment caused sustained
tumor regression and increased survival; however, early and late resistance was observed. Adaptive reactivation of RAS-MAPK signaling was abrogated in vitro by selective RTK (i.e., EGFR, FGFR) inhibitors, but responses were ineffective in vivo, whereas combination of
tipifarnib with the
MEK inhibitor
AZD6244 improved outcomes. A subset of
tumor-bearing mice treated with
tipifarnib developed acquired resistance. Whole-exome sequencing of resistant
tumors identified a Nf1
nonsense mutation and an activating mutation in Gnas at high allelic frequency, supporting the on-target effects of the drug. Cell lines modified with these genetic lesions recapitulated
tipifarnib resistance in vivo This study demonstrates the feasibility of targeting Ras membrane association in
cancers in vivo and predicts combination
therapies that confer additional benefit.Significance:
Tipifarnib effectively inhibits oncogenic HRAS-driven
tumorigenesis and abrogating adaptive signaling improves responses. NF1 and GNAS mutations drive acquired resistance to Hras inhibition, supporting the on-target effects of the drug.
Cancer Res; 78(16); 4642-57. ©2018 AACR.